Skip to main content
STLN $3.37 +5.31%
STLN logo
STLN · Starling Oncology, Inc.
Track STLN — free
$3.37 +0.17 (+5.31%) Play latest call Q2 2026 earnings call transcript
Market Cap
$326.37M
Shares
101.99M
Volume · Nov 19 201.51K Avg daily vol (3M) 2.45M
All webcasts

Earnings call · FY2026 Q3

Starling Oncology, Inc. (STLN) Q3 2026 Earnings Call

Concluded Nov 5, 2026
Nov 5, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $169.77M +24.3% YoY
Diluted EPS -$0.13
Net income -$15.75M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 5, 2026
Starling Oncology reported third-quarter revenue of $169.8 million, up 24.3% year over year, and Adjusted EBITDA of positive $3.4 million. It updated fiscal-year 2026 revenue guidance to $650 to $660 million and Adjusted EBITDA guidance to $4 to $6 million.
10-Q report · filed Nov 6, 2026
Starling Oncology reported third-quarter revenue of $169,767 and net loss of $(15,748), with figures in thousands; Adjusted EBITDA was $3,394. At September 30, 2026, cash was $36,895, and management expected liquidity for at least one year.

The audio replay and transcript follow the call.

Forward guidance

7 guided metrics

Management's latest ranges and targets are included below.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Forward guidance

From the 8-K filed Nov 5, 2026.

Metric Guided
Adjusted EBITDA
fourth quarter of 2026
$3M – $5M
Revenue table Lowered
Fiscal Year 2026
$650M – $660M
Gross Profit table Raised
Fiscal Year 2026
$107M – $110M
Adjusted EBITDA table Raised
Fiscal Year 2026
$4M – $6M
Capitated revenue Lowered
2026
$110M
Free Cash Flow table Lowered
Fiscal Year 2026
$5M – $10M
Medical Loss Ratio
2027
85% – 90%

Quarter detail

How the reported period landed and where the business moved.

Revenue · segments

Specialty Pharmacy Segment$109.30M +44% YoY
Patient Services Segment$60.01M -0.3% YoY
Clinical Trials and Other Segment$450,000 -5.1% YoY
Full-screen source Call document